Drug Type Small molecule drug |
Synonyms 2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine, Gosogliptin (USAN/INN), SatRx + [2] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (16 May 2016), |
Regulation- |
Molecular FormulaC17H26Cl2F2N6O |
InChIKeyVVNSEQJGCZQVOL-AXEKQOJOSA-N |
CAS Registry869490-47-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09625 | Gosogliptin | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | RU | 16 May 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | RU | 23 Apr 2013 | |
Chronic Kidney Diseases | Phase 1 | US | 01 Oct 2007 |
Phase 3 | 299 | Metformin+Gosogliptin | jzyfrdevnr(ywsguxqqib) = qxbqivffeg nhanelycgw (mspyfemnkg ) View more | Superior | 01 Jan 2016 | ||
Metformin+Vildagliptin | jzyfrdevnr(ywsguxqqib) = txmajyaxjt nhanelycgw (mspyfemnkg ) View more |